Global Virus Network

Last updated
Logo of the Global Virus Network Global Virus Network.png
Logo of the Global Virus Network

The Global Virus Network (GVN) is an international coalition of medical virologists whose goal is to help the international medical community by improving the detection and management of viral diseases. The network was founded in 2011 by Robert Gallo in collaboration with William Hall and Reinhard Kurth, and 24 countries were members of the network as of 2015. [1] The GVN fosters research into viruses that cause human disease to promote the development of diagnostics, antiviral drugs and vaccines, and its mission includes strengthening scientific training and response mechanisms to viral outbreaks. [1] The GVN has organized task forces for chikungunya, human T-lymphotropic virus, and Zika. [1] [2] [3] The network is headquartered at the Institute of Human Virology at the University of Maryland School of Medicine, and Gallo serves as its scientific director. [4]

Contents

Mission

The network's main mission is to tackle current broad viral threats as they develop, and to strengthen current research of viruses that cause human disease so as to prepare for any viral hazards. [5] Their mission is outlined by 3 steps that they take to achieve it, which are international collective research, ongoing training of upcoming generations of medical virologists (public education), and advocacy. [5] The GVN has grown to be a fundamental defense against diseases of viral nature. [6]

International collective research

The GVN uses small grants to provide training fellowships so virologists can address current viral challenges. [7] Global partnerships and mutual cooperation allows the GVN to span globally and to research viruses as they manifest and spread.[ citation needed ]

Public education

The GVN is also a source of credible information about viruses, vaccines, and breakthroughs in both fields, which they spread through digital and public speaking platforms. [7] The GVN promotes educational and valuable programs for future generations of scientists and biologists, and is a stable resource for both large governments and small organizations attempting to prepare themselves for viral threats. [8]

Advocacy

The final part of the GVN's mission is ensuring that funding persists, and that the network is able to provide up to date information through partnerships with governments and agencies across the world. [7] The GVN also advocates for further virology research to be performed and for more virology training opportunities worldwide.[ citation needed ]

Funding

All scientists and their research under the GVN are supported through various continuous small grants. The GVN works with governments as well as research companies to ensure that funding for both virology training and research are kept high enough to meet the demands of global health. [9] The GVN also receives funding from its partners, the Global Health Security Agenda (GHSA), the Coalition for Epidemic Preparedness Innovations (CEPI), and the Medical Technology Enterprise Consortium (MTEC). [10]

History and centers

The GVN has 34 centers across 17 nations, each of which has a medical virologist as its director who is willing to commit to GVN's mission. Each center also specializes in at least two areas of viral science. [11]

Centers

Source: [1]

Locations in the Middle East

Locations in Southern and Eastern Africa

Locations in Europe and Eurasia

Locations in Asia

Locations in North and South America

Accomplishments

GVN against the Chikungunya virus (CHIKV)

Chikungunya virus explained

CHIKV is a rapid-working onset febrile illness, of which the first visible symptom is a rash on the hands and arms. The virus causes a high fever and has the same intensity as that of an acute viral infection, similar to any virus present and visible in the bloodstream. [8]

What the GVN has done

The GVN was initially formed in 2011 in response to the outbreak of the Chikungunya virus, when it had just spread to the Western Hemisphere. While the GVN also discussed tackling the ongoing Ebola crisis centered around West Africa, the Chikungunya virus was their main priority at the time. CHIKV was discovered a little before 1968, and outbreaks had taken place everywhere from Thailand to the French Island of Réunion, where the virus at the time had caused 254 deaths. In 2013, the virus began to spread to the Caribbean and across the Atlantic to South America. The GVN is working toward antiviral drugs and vaccines against the Chikungunya virus, however one problem that the GVN has faced from the beginning is the limited ability to diagnose patients with the virus. As a result, the GVN was unable to control outbreaks in regions where the virus was most prominent because. However, so far the GVN has advanced the knowledge about the CHIKV infections, and has helped create a list of preventative measures which can be taken to stop the virus. [8]

In response to the ability of the virus to spread much more rapidly than initially thought, the GVN advanced efforts to learn more about and stop the virus. The network enlisted a task force to research CHIKV, for which researchers were selected based on their personal research, qualifications, and accomplishments. The task force is made up of 22 members, 3 co-chairs, and is overseen by Scott Weaver, John Fazakerley, and Marc Lecuit. The task force had 4 main tasks for the Chikungunya virus: [8] to find funding for CHIKV research, distribute information to journalists and health officials, advocate for more research on virus-carrying mosquitos, and to review the science of the disease in order to identify vaccines and to start drug trials. [8]

GVN against the Zika virus

Zika virus explained

Zika is a fast-acting virus that can be transferred through mosquito bites, and from a pregnant woman to her fetus. Currently, no vaccines or specific medication exist to treat the symptoms associated with the Zika virus, however there are general medications which limit the common symptoms of the virus. Common symptoms include fever, rash, headache joint pain, red eyes, and muscle pain. Symptoms typically don't last more than a week and people rarely die from this virus. [12] However, the virus poses a threat if it gets transferred to a fetus as it can cause birth defects, miscarriages, and stillbirths. [12]

GVN's Plan

The GVN also assembled a task force to tackle the Zika virus. Unlike the CHIKV task force, Membership to this task force is voluntary, and any GVN member who has research or new developments that can be used in response to the Zika virus epidemic could contribute it. Scott Weaver acts as chairman to the Zika task force, which reports to all GVN centers regarding news and information about the virus. The GVN's main goal is to be control outbreaks and contain them to one general area so the virus is easier to diagnose, control, and possibly treat. [12]

GVN against the Human T-Leukemia Virus (HTLV-1)

HTLV-1 explained

HTLV-1 affects one's T-cells, though the virus usually causes no visible signs or symptoms. [13] However, severe symptoms include motor changes in your limbs, an inflamed spinal cord, weakened legs, and cognitive impairment. Some people affected by the infection can develop adult T-cell Leukemia and can be predisposed to other severe medical conditions. This virus can spread through sexual contact, unsterile needles, and blood transfusions. It can also spread to a child from the mother's breast milk. There currently exist no treatments or cures for HTLV-1, and the condition lasts for a lifetime. However, it is not a major threat as roughly 95% of those infected are asymptomatic their whole life. [14]

GVN's Plan

The GVN has stated the importance of its work, which brings together the global community to conduct research and communicate about these viral problems that do not receive appropriate recognition in some areas. The task force made up of experts working on the HTLV-1 virus spans 11 countries, and is led by Dr. Robert Gallow in Maryland, Dr. Luc Willems in Belgium, and Dr. Hideki Hasegawa in Japan. The task force works daily to conduct research to hopefully stop HTLV-1, and the mission of the task force also includes funding drugs which can work to stop the virus from progressing into a disease. [15]

Related Research Articles

<span class="mw-page-title-main">Dengue fever</span> Tropical disease caused by the dengue virus, transmitted by mosquito

Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin 3 to 14 days after infection. These may include a high fever, headache, vomiting, muscle and joint pains, and a characteristic skin itching and skin rash. Recovery generally takes two to seven days. In a small proportion of cases, the disease develops into a more severe dengue hemorrhagic fever, resulting in bleeding, low levels of blood platelets and blood plasma leakage, or into dengue shock syndrome, where dangerously low blood pressure occurs.

<span class="mw-page-title-main">Chikungunya</span> Infection caused by the Chikungunya virus

Chikungunya is an infection caused by the Chikungunya virus (CHIKV). The disease was first identified in 1952 in Tanzania and named based on the Kimakonde words for "to become contorted". Symptoms include fever and joint pain. These typically occur two to twelve days after exposure. Other symptoms may include headache, muscle pain, joint swelling, and a rash. Symptoms usually improve within a week; however, occasionally the joint pain may last for months or years. The risk of death is around 1 in 1,000. The very young, old, and those with other health problems are at risk of more severe disease.

<span class="mw-page-title-main">Epidemiology of chikungunya</span>

Chikungunya is a mosquito-borne alpha virus that was first isolated after a 1952 outbreak in modern-day Tanzania. The virus has circulated in forested regions of sub-Saharan African in cycles involving nonhuman primate hosts and arboreal mosquito vectors. Phylogenetic studies indicate that the urban transmission cycle—the transmission of a pathogen between humans and mosquitoes that exist in urban environments—was established on multiple occasions from strains occurring on the eastern half of Africa in non-human primate hosts. This emergence and spread beyond Africa may have started as early as the 18th century. Currently, available data does not indicate whether the introduction of chikungunya into Asia occurred in the 19th century or more recently, but this epidemic Asian strain causes outbreaks in India and continues to circulate in Southeast Asia.

The National Institute of Virology in Pune, India is an Indian virology research institute and part of the Indian Council of Medical Research (ICMR). It was previously known as 'Virus Research Centre' and was founded in collaboration with the Rockefeller Foundation. It has been designated as a WHO H5 reference laboratory for SE Asia region.

<span class="mw-page-title-main">Robert Gallo</span> American biomedical researcher

Robert Charles Gallo is an American biomedical researcher. He is best known for his role in establishing the human immunodeficiency virus (HIV) as the infectious agent responsible for acquired immune deficiency syndrome (AIDS) and in the development of the HIV blood test, and he has been a major contributor to subsequent HIV research.

Edward McSweegan is an American microbiologist, science writer and fiction author.

Clarence James Peters, Jr is a physician, field virologist and former U.S. Army colonel. He is noted for his efforts in trying to stem epidemics of exotic infectious diseases such as the Ebola virus, Hanta virus and Rift Valley fever (RVF). He is an eminent authority on the virology, pathogenesis and epidemiology of hemorrhagic fever viruses.

<span class="mw-page-title-main">Vaccine Research Center</span>

The Vaccine Research Center (VRC), is an intramural division of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), US Department of Health and Human Services (HHS). The mission of the VRC is to discover and develop both vaccines and antibody-based products that target infectious diseases.

<span class="mw-page-title-main">Mosquito-borne disease</span> Diseases caused by bacteria, viruses or parasites transmitted by mosquitoes

Mosquito-borne diseases or mosquito-borne illnesses are diseases caused by bacteria, viruses or parasites transmitted by mosquitoes. Nearly 700 million people get a mosquito-borne illness each year, resulting in over 725,000 deaths.

<i>Zika virus</i> Species of flavivirus

Zika virus is a member of the virus family Flaviviridae. It is spread by daytime-active Aedes mosquitoes, such as A. aegypti and A. albopictus. Its name comes from the Ziika Forest of Uganda, where the virus was first isolated in 1947. Zika virus shares a genus with the dengue, yellow fever, Japanese encephalitis, and West Nile viruses. Since the 1950s, it has been known to occur within a narrow equatorial belt from Africa to Asia. From 2007 to 2016, the virus spread eastward, across the Pacific Ocean to the Americas, leading to the 2015–2016 Zika virus epidemic.

Christopher Mores is an American (US) arbovirologist, trained in infectious disease epidemiology. He is a professor in the Department of Global Health at the Milken Institute School of Public Health, the program director for the Global Health Epidemiology and Disease Control MPH program, and is director of a high-containment research laboratory at the George Washington University in Washington, DC.

<span class="mw-page-title-main">2015–16 Zika virus epidemic</span> Widespread epidemic of Zika fever

An epidemic of Zika fever, caused by Zika virus, began in Brazil and affected other countries in the Americas from April 2015 to November 2016. The World Health Organization (WHO) declared the end of the epidemic in November 2016, but noted that the virus still represents "a highly significant and long term problem". It is estimated that 1.5 million people were infected by Zika virus in Brazil, with over 3,500 cases of infant microcephaly reported between October 2015 and January 2016. The epidemic also affected other parts of South and North America, as well as several islands in the Pacific.

In October 2013, there was an outbreak of Zika fever in French Polynesia, the first outbreak of several Zika outbreaks across Oceania. With 8,723 cases reported, it was the largest outbreak of Zika fever before the outbreak in the Americas that began in April 2015. An earlier outbreak occurred on Yap Island in the Federated States of Micronesia in 2007, but it is thought that the 2013–2014 outbreak involved an independent introduction of the Zika virus from Southeast Asia. Investigators suggested that the outbreaks of mosquito-borne diseases in the Pacific from 2012 to 2014 were "the early stages of a wave that will continue for several years", particularly because of their vulnerability to infectious diseases stemming from isolation and immunologically naive populations.

<span class="mw-page-title-main">John P. Woodall</span> American entomologist

John Payne Woodall (1935–2016), known as Jack Woodall, was an American-British entomologist and virologist who made significant contributions to the study of arboviruses in South America, the Caribbean and Africa. He did research on the causative agents of dengue fever, Crimean–Congo hemorrhagic fever, o'nyong'nyong fever, yellow fever, Zika fever, and others.

Dr. Manmohan Parida, Sc ‘G’ assumed the charge of Director DRDE, Gwalior with effect from 1 October 2021. He obtained his graduation in Veterinary Science from Odisha Veterinary College as best graduate with three Gold Medals into his credit. He earned his master's degree in Veterinary Virology from prestigious Indian Veterinary Research Institute, Mukteswar and further obtained his Doctorate Jiwaji University, Gwalior in Microbiology. He was also awarded with Monbusho Fellowship from Japanese Govt and pursued Post Doctoral Research Scientist at Institute of Tropical Medicine, WHO reference center for research on arboviruses, Nagasaki, Japan.

The Institute of Advanced Virology (IAV) has been established by the Government of Kerala through Kerala Biotechnology Commission (KBC) of Kerala State Council for Science Technology and Environment (KSCSTE) on the wake of the 2018 Nipah virus outbreak in Kerala.

William W. Hall is the chair of medical microbiology and professor emeritus at the Centre for Research in Infectious Diseases at University College Dublin.

Science diplomacy is the collaborative efforts by local and global entities to solve global issues using science and technology as a base. In science diplomacy, collaboration takes place to advance science but science can also be used to facilitate diplomatic relations. This allows even conflicting nations to come together through science to find solutions to global issues. Global organizations, researchers, public health officials, countries, government officials, and clinicians have previously worked together to create effective measures of infection control and subsequent treatment. They continue to do so through sharing of resources, research data, ideas, and by putting into effect laws and regulations that can further advance scientific research. Without the collaborative efforts of such entities, the world would not have the vaccines and treatments we now possess for diseases that were once considered deadly such as tuberculosis, tetanus, polio, influenza, etc. Historically, science diplomacy has proved successful in diseases such as SARS, Ebola, Zika and continues to be relevant during the COVID-19 pandemic today.

Rosemary Chepkorir Sang is a Kenyan virologist at the Kenya Medical Research Institute, who specialises in the transmission and treatment of arboviruses. She has a PhD in zoology and an MSc in medical virology and entomology. She has investigated several major outbreaks of arbovirus in East Africa. She has been outspoken on the need for African countries to be part of global policy discussions on climate change. During the COVID-19 pandemic she expressed concern about the welfare of street children. She has been a member of a number of Expert Committees for the World Health Organization, including on International Health Regulation, and Rift Valley fever. She was elected a Fellow of the African Academy of Sciences in 2014.

<span class="mw-page-title-main">Sunit Kumar Singh</span> Indian molecular biologist

Sunit Kumar Singh is an Indian molecular virologist and professor of Molecular Immunology & Virology at the Institute of Medical Sciences, Banaras Hindu University. Currently he is the director of the Dr B R Ambedkar Center for Biomedical Research (ACBR), New Delhi.

References

  1. 1 2 3 4 McSweegan E, Weaver SC, Lecuit M, Frieman M, Morrison TE, Hrynkow S (August 2015). "The Global Virus Network: Challenging chikungunya". Antiviral Research. 120: 147–52. doi:10.1016/j.antiviral.2015.06.003. PMC   4843800 . PMID   26071007.
  2. Leading Virologists Join Together to Tackle Viruses, Leukemia and Neurologic Disorders, GVN, archived from the original on 4 March 2016, retrieved 25 February 2016
  3. "Zika Virus Task Force". Global Virus Network. 16 February 2016. Retrieved 2016-02-25.
  4. Mann A (2011), "New organization pledges scientific expertise for viral outbreaks", Nature Medicine , 17 (4): 394, doi:10.1038/nm0411-394a, PMC   7095820 , PMID   21475210
  5. 1 2 "Global Virus Network - Center for Integrated Global Health Sciences - University at Buffalo". www.buffalo.edu. Retrieved 2018-11-22.
  6. "Global Virus Network - Center for Integrated Global Health Sciences - University at Buffalo". www.buffalo.edu. Retrieved 2018-12-01.
  7. 1 2 3 "About – GVN". gvn.org. Retrieved 2018-11-22.
  8. 1 2 3 4 5 McSweegan, Edward; Weaver, Scott C.; Lecuit, Marc; Frieman, Matthew; Morrison, Thomas E.; Hrynkow, Sharon (August 2015). "The Global Virus Network: Challenging chikungunya". Antiviral Research. 120: 147–152. doi:10.1016/j.antiviral.2015.06.003. ISSN   0166-3542. PMC   4843800 . PMID   26071007.
  9. "Global Virus Network - Center for Integrated Global Health Sciences - University at Buffalo". www.buffalo.edu. Retrieved 2018-11-16.
  10. "Partners – GVN". gvn.org. Retrieved 2018-11-29.
  11. "GVN Centers – GVN". gvn.org. 6 June 2018. Retrieved 2018-11-16.
  12. 1 2 3 "What We Know About Zika". CDC. 2018-06-06. Retrieved 2018-11-29.
  13. "Human T-cell leukemia virus type 1 | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 2018-11-29.
  14. "HTLV-1 Task Force – GVN". gvn.org. Retrieved 2018-11-30.
  15. "HTLV-1 Task Force – GVN". gvn.org. Retrieved 2018-11-29.